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Aims Mendelian randomization uses genetic variants related to environmentally modiﬁable risk factors in an attempt to
improve causal inference from observational data. We examined the effect of lifetime body mass index (BMI) on
adult carotid intima-media thickness (CIMT) and various atherosclerotic risk factors by using both Mendelian ran-
domization and conventional analyses.
Methods
and results
A total of 2230 individuals (1218 women), aged 3–18 at study induction, took part in clinical examinations in 1980, 1983,
1986,and,mostrecently,2001whentheywereaged24–39.IntheseanalysesweutilizedtheknownrelationbetweenFTO
polymorphism rs9939609 and BMI. The dose–response association between the number of A alleles in FTO and higher
mean BMI from childhood to adulthood was conﬁrmed, but no associations with potential confounding factors were
observed. In standard regression models, lifetime BMI was associated with adult CIMT, lifetime systolic blood pressure,
adult fasting glucose, and adult HOMA-index. When variation in FTO was used as an instrument for unconfounded BMI
levels,similarorlargereffectsoflifetimeBMIonallthesephenotypeswerefound,althoughwithwiderconﬁdenceintervals.
Conclusion Mutually supportive results from Mendelian randomization and standard regression models strengthen the evidence
of the effect of lifetime BMI on atherosclerosis risk in young adults.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The limitations of observational cohort studies to determine causal
associations between hypothesized risk factors and important
chronic diseases, such as coronary heart disease (CHD), are
well documented.
1 First, because many potential risk factors are
associated with a range of other predictor variables, observed
associations may be because of confounding. Secondly, because
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2 reverse causality, where early
stages of atherosclerosis and/or preclinical heart disease affect risk
factor levels, rather than vice versa, also remains a distinct
possibility.
Mendelian randomization has recently been advanced as a
means of dealing with both confounding and reverse causality.
This approach is predicated upon the random assortment of
alleles at the time of gamete formation that leads to population dis-
tributions of genetic variants that are generally independent of the
environmental exposures that commonly confound epidemiologi-
cal risk factors–disease associations.
3–6 These unconfounded
differences in risk factor levels should therefore translate into
differences in disease occurrence if the exposure is truly causally
related to the disease. Moreover, genetic variants will not be inﬂu-
enced by the existing cardiovascular pathology and therefore
reverse causation will not distort the association between geno-
type and disease in the way it would distort the relationship
between risk factor levels measured in adulthood and disease.
Finally, genetic variants typically affect relevant protein levels
throughout life, so reducing the problem of attenuation of
effects (regression dilution bias) common in cohort studies with
extended follow-up.
Data from the Cardiovascular Risk in Young Finns study
7
enabled us to examine the associations of lifetime body mass
index (BMI, kg/m
2) with adult carotid intima-media thickness
(CIMT), a valid preclinical marker of CHD, and atherosclerotic
risk factors, such as blood pressure, lipids, and C-reactive
protein, across the life course from age 3–39 years in a racially
homogenous white European population. We utilized the known
association of variants in the FTO gene with BMI
8–11 to examine
whether the Mendelian randomization approach would provide
support for a causal association between lifetime BMI and athero-
sclerosis risk (Figure 1). Thus, individuals with A alleles in the FTO
polymorphism rs9939609 are predisposed to higher adiposity
8 and
they have in effect been randomly allocated to somewhat higher
levels of BMI than individuals with other genotypes related to
lower adiposity (paths a and b). Eventually, these differences in
BMI should confer differences in atherosclerosis and atherosclero-
tic risk (path c) factors if BMI was causally related to them and
population stratiﬁcation did not confound the associations.
12 To
our knowledge, this is the ﬁrst Mendelian randomization study to
examine the effect of lifetime BMI on atherosclerosis risk based
on direct structural vascular measurement.
Methods
Study population
The Young Finns study is a multicentre follow-up study of cardiovascu-
lar risk factors in Finnish children and adolescents.
7,13 The original
sample was 4320 Caucasian children and adolescents aged 3, 6, 9,
12, 15, and 18 years who were randomly sampled from ﬁve areas of
Finland using the national register. The baseline examination was con-
ducted in 1980, with response being 83% (3596 of those invited).
Follow-ups were conducted in 1983, 1986, and, the latest, 2001
when the participants had reached 24–39 years of age. The 2230 indi-
viduals (1012 men and 1218 women) with full data on FTO polymorph-
ism rs9939609 and BMI in childhood and adulthood formed the
present analytical sample (Figure 2). Differences in the baseline charac-
teristics of participants and non-participants were small but achieved
statistical signiﬁcance owing to the large numbers: BMI (17.9 vs.
17.8 kg/m
2, P ¼ 0.22); age (10.7 vs. 10.0 years, P , 0.0001); and sex
(55% vs. 45% female, P , 0.0001). The study was conducted according
to the guidelines of the Helsinki declaration, and the study protocol
was approved by local ethics committees. All participants gave their
full informed consent.
FTO genotyping
Genomic DNAwas extracted from peripheral blood leucocytes using a
commercially available kit and Qiagen BioRobot M48 Workstation
according to the manufacturer’s instructions (Qiagen Inc., Hilden,
Germany). We genotyped FTO single nucleotide polymorphism (SNP)
rs9939609 by employing the 50 nuclease assay and ﬂuorogenic allele-
speciﬁc TaqMan MGB probes,
14 using the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA, USA). The
samples were pipetted using an automated TECAN Freedom
Figure 1 The Mendelian randomization using instrumental variables regression analysis examines whether lifetime BMI, to the extent it is
associated with FTO genotype (path a), predicts atherosclerosis risk (path c). FTO genotype is expected to be unrelated to confounding
factors (path b) and thus the effects of confounding factors (path d) are expected to be eliminated in the analysis. Conventional regression
analysis, in contrast, is open to bias because of unmeasured or imprecisely measured confounding factors.
FTO, BMI, and atherosclerosis risk 2553EVO-100 instrument (Tecan Group Ltd, Ma ¨nnedorf, Switzerland). The
nucleotide sequencesoftheprimers andprobesusedinthepolymerase
chain reaction (PCR) were deduced from published sequences depos-
ited in the GenBank and Celera databases and synthesized by Applied
Biosystems. The PCR containing genomic DNA, 1  Universal PCR
MasterMix,900 nMofeachprimerand200 nMofeachprobewereper-
formedin384-wellplatesusingthestandardprotocolinatotalvolumeof
5 mL. Endpoint ﬂuorescence was measured post-PCR and genotype
calling carried out by the allelic discrimination analysis module (ABI
Prism SDS software, ABI, Foster City, CA, USA). Random duplicates
wereusedasqualitycontrol.AllgenotypeswereanalysedintheDepart-
ment of Clinical Chemistry at Tampere University Hospital and Univer-
sity of Tampere.
Body mass index and other life course
atherosclerotic risk factors
Life course measures were based on repeated assessments in 1980
(participant age range 3–18 years), 1983 (6–21 years), 1986 (9–24
years), and 2001 (24–39 years), except C-reactive protein, which
was assessed in 1980 and 2001 only. Measurements of weight (kg)
and height (mm) were obtained using standard research protocols
and were used to calculate BMI (weight in kg/height
2 in m).
15 Measure-
ments of blood pressure were taken with the participant in the sitting
position after 5 min rest with a mercury sphygmomanometer (for the
3 year olds with ultrasound device, Arteriosonde 1020, Roche) in
1980, 1983, and 1986 and with a random zero sphygmomanometer
(Hawksley & Sons Ltd, West Sussex, UK) in 2001.
16,17 Readings to
the nearest even number of millimetres of mercury were performed
at least three times on each subject; the average of the systolic
blood pressure measurements was used in the analysis.
In 1980, 1983, 1986, and 2001, all blood samples were taken after an
overnight fast and analysed in duplicate in the same laboratory on each
time occasion.
7 Standard enzymatic methods were used for serum
total cholesterol, HDL-cholesterol and triglycerides, and plasma
glucose concentrations. LDL-cholesterol concentration was calculated
using the Friedewald formula.
18 In 2001, we assessed serum
high-sensitive C-reactive protein using an automated analyser (Olympus
AU400, Olympus, USA) and a highly sensitive turbidimetric immu-
noassay kit (CRP-UL-assay, Wako Chemicals, Neuss, Germany).
Serum C-reactive protein samples taken in 1980 were stored at
2208C and analysed in 2005 using the same method as in 2001.
During the storage, the samples were not thawed or refrozen.
Carotid intima-media thickness and
adulthood atherosclerotic risk factors
In 2001–2002, ultrasound studies were performed using Sequoia 512
ultrasound mainframes (Acuson, Mountain View, CA, USA) to
measure CIMT. The measurement has previously been described in
detail.
7,19 In brief, the image was focused on the posterior (far) wall
of the left carotid artery. A minimum of four measurements of the
common carotid far wall were taken approximately 10 mm proximal
to the carotid bifurcation to derive mean carotid IMT. The digitally
stored scans were manually analysed by one reader blinded to sub-
jects’ details (M.J.). The between-visit coefﬁcient of variation of IMT
measurements was 6.4%.
Several additional assessments were carried out in 2001.
20 Waist
circumference (mm, measured in duplicate at the level of the twelfth
rib or level with the navel in thin subjects) and hip circumference
(mm) were obtained to calculate waist–hip ratio. Standard enzymatic
methods were used for plasma glucose concentrations. Serum insulin
was measured by microparticle enzyme immunoassay kit (Abbott Lab-
oratories, Diagnostic Division, Dainabot). Insulin resistance was esti-
mated according to the homeostasis model as the product of fasting
glucose and insulin divided by the constant 22.5, i.e. the HOMA
index.
21 Serum apolipoproteins A-1 and B were analysed immunotur-
bidometrically (Orion Diagnostica, Espoo, Finland).
Parental factors and adult lifestyle factors
Parental socioeconomic position was measured in 1980 using parental
occupational status as classiﬁed by Statistics Finland and categorized as
manual vs. non-manual.
22 Where socioeconomic position differed
between parents, data on the parent with the higher occupational
status were used. Parental BMI in 1980 was calculated from self-
reported height and weight.
The participant’s own adult socioeconomic position was measured
in 2001 by occupational status and categorized as for parental socioe-
conomic position. Educational attainment was categorized as academic;
secondary education but not academic; and comprehensive school as
the highest level of education. Information on adult smoking (status
and pack-years of tobacco smoking) and alcohol consumption (units
per week) was obtained by questionnaire in 2001. One unit of
alcohol (12 g) was equal to a glass of wine, a single 4 cL measure of
spirits or a 33 cL bottle of beer.
20
Statistical analysis
Statistical signiﬁcance in all tests was inferred at a two-tailed P , 0.05.
The following tests were performed.
Figure 2 Sample selection.
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We tested the Hardy–Weinberg equilibrium at FTO SNP locus, on a
contingency table of observed vs. predicted genotypic frequencies,
with an exact test to evaluate whether genotyping error, biological
selection bias, or other population non-homogeneity was likely in
our data. The genotype frequencies in the FTO polymorphism were
in Hardy–Weinberg equilibrium (P . 0.20), thus supporting the integ-
rity of our genetic data.
Test of genotype–phenotype associations
We constructed lifetime phenotype measures for BMI, height, systolic
blood pressure, total cholesterol, HDL- and LDL-cholesterol, and C-
reactive protein by calculating age-standardized z-scores (mean ¼ 0,
standard deviation ¼ 1) for each age and for men and women separ-
ately and then averaged across ages within each measure and partici-
pant. We used the logarithm of C-reactive protein to correct for its
positively skewed distribution. There was no strong evidence of FTO
polymorphism   sex interaction on any of the phenotype measures
(all P . 0.11), thus the main analysis was conducted for men and
women in combination. We used linear regression analysis to study
the age- and sex-adjusted associations of the FTO genotype (per A
allele) with phenotype measures. Since our analyses are all hypothesis
driven and hence equivalent to a candidate gene approach, we used
conventional alpha levels to detect statistically signiﬁcant associations
without adjusting for multiple testing. These analyses were performed
with Statistical Analysis System (SAS, version 9.1).
Instrumental variables regression analysis
As in previous studies using the Mendelian randomization
approach,
23–31 we performed an instrumental variables regression
analysis to examine if the FTO polymorphism was associated with
CIMT and atherosclerotic risk factors through its association with
BMI levels. We compared the results from the instrumental variable
estimates of the association between lifetime BMI and phenotype
measures (i.e. path c in Figure 1) to those from standard linear
regression using the Durbin form of the Durbin–Wu–Hausman stat-
istic.
32 We used the F-statistics from the ﬁrst-stage regressions to
evaluate the strength of the instruments, i.e. path a in Figure 1
(values .10 are taken to indicate sufﬁcient strength to ensure the val-
idity of instrumental variable methods).
33,34 Instrumental variable
regression analysis was performed with Stata (version 9.2, Stata Insti-
tute, TX, USA).
An additional analysis with a simulated data set was carried out to
examine the change in precision of the results from the instrumental
variable regression analyses if our sample size was substantially larger.
First, we ﬁlled the missing values in the baseline sample (n ¼ 3596) by
multivariate imputation method of ICE in Stata software, with
missing-at-random assumptions [n ¼ 1410 (39%) had some missing
data]. In addition to all the variables in the analyses, the imputation
process included baseline predictors of dropout from the cohort,
such as BMI (available from all but one baseline participant). We
imputed two independent copies of the complete baseline data
and treated them as one artiﬁcially created simulated data set with
a sample size of 7192. Both standard and instrumental variables
regression analyses were then run with this large simulated data
set. To examine whether the obtained estimates were robust,
we repeated this procedure ﬁve times, thus creating ﬁve
independent simulated data sets, and compared estimates between
the simulations.
Results
Characteristics of the study population are shown in Table 1.
Variation in FTO (rs9939609) was not associated with potential
confounding factors, such as age, sex, socioeconomic circum-
stances, education, or risk behaviours (Table 2) supporting the
assumption that the variation in the FTO genotype is independent
of potential confounding factors (path b in Figure 1). In contrast,
lower parental socioeconomic position and participant’s lower
educational attainment were associated with higher lifetime BMI
(P , 0.05), demonstrating that observed BMI is affected by
potential confounding factors (path d in Figure 1).
Gene-phenotype associations
FTO polymorphism explained 0.4% of the variation in lifetime BMI.
Each additional copy of the A allele in the FTO gene was associated
with higher lifetime BMI, with higher maternal BMI and, more
weakly, paternal BMI (Table 3). FTO polymorphism was also associ-
ated with higher lifetime systolic blood pressure, but no association
was found with lipids or C-reactive protein. The association
between FTO polymorphism and lifetime systolic blood pressure
attenuated after adjustment for lifetime BMI (adjusted change per
A allele, 0.05; 95% CI, 20.01, 0.10; P ¼ 0.11), suggesting that adi-
posity as indexed by BMI at least partially mediates this association.
Of the adulthood outcomes, a greater number of A alleles was
associated with higher BMI (although less strongly than with lifetime
BMI), larger waist circumference, and higher fasting glucose levels.
Adjustment for BMI and waist circumference had little effect on
the association between FTO polymorphism and fasting glucose
(adjusted change per A allele 0.05; 95% CI, 0.01, 0.10; P ¼ 0.03).
A greater number of A alleles was weakly associated with greater
CIMT and higher insulin resistance. Progression of atherosclerosis
is more rapidinmen thaninpre-menopausal women.In sex-speciﬁc
analysis,eachadditional copyof A allelewasassociated with a CIMT
increaseof 0.009 mm (95% CI, 0.000, 0.017; P ¼ 0.049) in men. This
ﬁgure was 0.000 mm (95% CI, 20.006, 0.007; P ¼ 0.95) in women
(P for sex interaction ¼ 0.11; for all other genotype associations, P
for sex interaction exceeded 0.2). Adjustment for BMI and waist
circumference slightly reduced the effect of FTO genotype on CIMT
in men(per A allele change, 0.008; 95% CI, 20.001, 0.016; P ¼ 0.08).
Standard regression analysis and
instrumental variables regression analysis
The standard regression analysis suggests positive associations of
lifetime BMI with adult CIMT, lifetime systolic blood pressure,
adult glucose, and adult insulin resistance (Table 4, upper panel).
In the instrumental variables regression analysis with FTO poly-
morphism as the instrument for unconfounded lifetime BMI
levels (path a in Figure 1), all the effects of BMI on CIMT and
other phenotypes are in the same direction but less precisely esti-
mated (P-values range between 0.02 and 0.15). In general, the
effects appeared larger in the instrumental analysis than in the
standard regression analysis, but only for adult fasting glucose
does the difference in effect sizes between the two analyses
reach conventional statistical signiﬁcance. The wide conﬁdence
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that our data, despite the relatively large sample size, had
limited power for the instrumental variable analyses (i.e. path a
in Figure 1 was relatively weak). Indeed, F-values in the ﬁrst-stage
regression testing the strength of instruments were ,10 (range,
7.5–9.2). Running these analyses with FTO haplotypes as
instruments did not solve this problem as the strength of instru-
ment was not improved (see Supplementary material online,
Appendix 1).
The lower panel of Table 4 shows the results from the standard
and instrumental variables regression analyses using simulated data
corresponding to ours, but the sample size increased two-fold to
that we had at the baseline (i.e. n ¼ 2   3596). In such data,
F-value in the ﬁrst-stage regression is 31.6; all of the associations of
lifetime BMI with CIMT and atherosclerotic risk factors were now
robust in instrumental variables regression analysis and for all out-
comes except HOMA index these associations were of greater
magnitude compared with those in the standard regression analyses.
We repeated these analyses with ﬁve independently simulated data
sets. The associations in instrumental variables regression analysis
andstandardregressionanalysisremainedacrossallofthesimulations
repeated ﬁve times, whereas the difference in the magnitude of
the associations between the two analyses was consistently
replicated only for adult glucose (see Supplementary material
online, Appendix 2).
Discussion
This study took advantage of the robust association between
FTO polymorphism rs9939609 and BMI to conduct a Mendelian
randomization analysis on the effect of lifetime BMI on CIMT
and various atherosclerotic risk factors in a cohort of young
adults. As expected, standard regression analysis showed lifetime
BMI to be associated with greater adult CIMT, higher lifetime
............................................... ...............................................
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Table 1 Characteristics of study sample
Female Male
n Mean (SD) or% n Mean (SD) or %
Mean age at baseline (year) 1218 10.7 (5.0) 1012 10.7 (5.0)
FTO genotype (rs9939609) (%)
TT 420 34.5 367 36.3
TA 592 48.6 495 48.9
AA 206 16.9 150 14.8
Mother’s BMI (kg/m
2) 1185 24.0 (3.8) 986 23.9 (3.7)
Father’s BMI (kg/m
2) 1069 25.5 (3.1) 873 25.4 (3.1)
BMI in childhood and adolescence (kg/m
2)
Age 3 173 15.5 (1.2) 148 15.6 (1.0)
Age 6 371 15.6 (1.7) 290 15.5 (1.7)
Age 9 562 16.6 (2.3) 465 16.6 (2.1)
Age 12 600 18.3 (2.7) 485 18.1 (2.6)
Age 15 601 20.2 (2.5) 503 20.0 (2.5)
Age 18 554 21.2 (2.6) 429 21.5 (2.7)
Adult measures (age 24–39)
Carotid IMT (mm) 1207 0.573 (0.084) 1004 0.593 (0.100)
BMI (kg/m
2) 1218 24.5 (4.6) 1012 25.7 (4.1)
Waist–hip ratio 1218 0.79 (0.06) 1012 0.90 (0.06)
Waist circumference (mm) 1218 794 (114) 1012 898 (108)
Height (cm) 1218 166.0 (59.6) 1012 179.5 (65.4)
Systolic BP (mmHg) 1205 116.0 (12.4) 1000 129.3 (13.5)
TC (mmol/L) 1218 5.05 (0.91) 1012 5.26 (1.04)
HDL-cholesterol (mmol/L) 1218 1.39 (0.30) 1010 1.16 (0.28)
LDL-cholesterol (mmol/L) 1218 3.14 (0.77) 1010 3.42 (0.92)
TG (mmol/L) 1218 1.16 (0.67) 1012 1.54 (1.00)
Log C-reactive protein (mmol/L) 1218 20.09 (1.82) 1012 20.54 (1.65)
Glucose (mmol/dL) 1218 4.92 (0.74) 1012 5.23 (0.92)
Insulin (mmol/dL) 1218 7.83 (5.92) 1011 7.72 (5.80)
HOMA index 1218 1.77 (1.80) 1011 1.87 (2.01)
Apolipoprotein A-1 (g/L) 1218 1.56 (0.26) 1012 1.40 (0.21)
Apolipoprotein B (g/L) 1218 0.99 (0.24) 1012 1.14 (0.27)
M. Kivima ¨ki et al. 2556systolic blood pressure, higher adult fasting glucose, and
higher HOMA index. When FTO polymorphism was used as an
instrument for non-confounded BMI levels, similar or larger
effects of lifetime BMI on all these phenotypes were found, but
for statistically robust ﬁndings our sample size would need to
be considerably larger.
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Table 2 Associations between FTO polymorphism rs9939609 and potential confounding factors
n % or mean (SD) by FTO genotype Change
a (95% CI) P for trend
a
TT AT AA Per A allele
Sex (% of men) 2230 46.6 45.5 42.1 20.02 (20.05, 0.01) 0.19
Age (years)
b 2230 10.6 (4.9) 10.6 (5.0) 11.0 (5.1) 0.15 (20.15, 0.45) 0.32
Parental socioeconomic position (% of manual)
b 2171 38.4 40.6 39.5 0.01 (20.02, 0.04) 0.62
Own adult socioeconomic position (% of manual)
c 1918 32.4 33.1 31.8 0.00 (20.03, 0.03) 0.88
Education (% of academic)
c 2218 16.8 19.9 19.0 0.001 (20.002, 0.005) 0.21
Smoking (% of smokers)
c 2170 24.6 24.1 25.3 0.00 (20.02, 0.03) 0.77
Pack-years among smokers
c 507 10.2 (7.9) 9.2 (6.5) 9.1 (7.2) 20.34 (21.17, 0.48) 0.41
Alcohol consumption (units per week)
c 2199 6.3 (9.2) 5.8 (8.0) 7.0 (8.1) 20.12 (20.61, 0.37) 0.64
aAdjusted for age and sex.
bParticipants at age 3–18.
cMeasured at age 24–39.
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Table 3 Associations between FTO polymorphism rs9939609 and phenotypes across the life course and in adulthood
n Mean (SD) by FTO genotype Change
a (95% CI) P for trend
a
TT AT AA Per A allele
Parental phenotype
Mother’s BMI, kg/m
2 2171 23.7 (3.7) 23.9 (3.7) 24.5 (4.1) 0.36 (0.14, 0.58)
b 0.001
Father’s BMI, kg/m
2 1940 25.3 (3.1) 25.6 (3.1) 25.6 (3.0) 0.14 (20.06, 0.34)
b 0.16
Lifetime phenotype
c (mean z-score)
BMI 2230 20.07 (0.99) 0.02 (1.01) 0.11 (0.98) 0.09 (0.03, 0.15) 0.003
Systolic BP 2204 20.06 (1.02) 0.01 (0.97) 0.10 (1.03) 0.08 (0.02, 0.14) 0.01
TC 2226 20.01 (1.00) 0.01 (0.98) 20.05 (1.04) 20.01 (20.07, 0.05) 0.70
HDL-cholesterol 2224 0.01 (1.01) 20.02 (0.99) 0.03 (1.01) 0.00 (20.06, 0.06) 0.95
LDL-cholesterol 2224 20.01 (0.99) 0.01 (0.99) 20.05 (1.05) 20.01 (20.07, 0.05) 0.69
TG 2228 20.02 (1.06) 0.02 (0.97) 20.06 (0.96) 20.01 (20.07, 0.05) 0.85
C-reactive protein
d 2133 20.02 (1.02) 20.01 (0.98) 0.07 (1.00) 0.04 (20.02, 0.10) 0.22
Adult phenotype
e
CIMT, mm 2211 0.578 (0.087) 0.582 (0.095) 0.587 (0.097) 0.003 (20.001, 0.009) 0.14
BMI, kg/m
2 2230 24.9(4.5) 25.1 (4.3) 25.4 (4.5) 0.28 (0.02, 0.54) 0.04
Waist–hip ratio 2230 0.840 (0.080) 0.841 (0.083) 0.845 (0.082) 0.003 (20.000, 0.007) 0.07
Waist circumference, mm 2230 837 (123) 842 (122) 848 (124) 6.5 (20.1, 13.0) 0.05
Height, cm 2230 172.1 (8.9) 172.3 (9.1) 171.6 (9.6) 0.1 (20.3, 0.5) 0.60
Glucose, mmol/dL 2230 5.04 (0.71) 5.03 (0.65) 5.19 (1.41) 0.06 (0.01, 0.11) 0.01
Insulin, mmol/dL 2229 7.50 (4.79) 8.01 (6.58) 7.69 (5.71) 0.18 (20.17, 0.54) 0.31
HOMA index 2229 1.73 (1.44) 1.86 (2.05) 1.88 (2.28) 0.08 (20.03, 0.20) 0.13
Apolipoprotein A-1, g/L 2230 1.50 (0.25) 1.48 (0.24) 1.50 (0.27) 20.01 (20.02, 0.01) 0.43
Apolipoprotein B, g/L 2230 1.06 (0.27) 1.06 (0.26) 1.04 (0.27) 20.01 (20.02, 0.01) 0.35
Note P for all interactions with sex   0.11.
aAdjusted for age and sex.
bAnalysis is additionally adjusted for parental age.
cMeasured at ages 3, 6, 9, 12, 15, 18, 24, 27, 30, 33, 36, and 39 years. Only those participants with data measured in adulthood (age 24–39) and at least once between ages 3–18
included in the analysis.
dStandardized after logarithmic transformation.
eMeasured at age 24–39.
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approach
At least three issues suggest that Mendelian randomization
approach may add to the evidence from conventional cohort
studies in testing the contribution of lifetime BMI to atherosclerosis
risk. First, conﬁrming previous studies, FTO polymorphism was
associated with BMI (path a in Figure 1).
8–11 This association was
stronger for lifetime BMI than adult BMI, which is, as would be
expected, given that genotypes should have life-long inﬂuence on
risk factor levels.
35 Our analysis using the FTO genotype as an
instrument for life-long BMI levels is therefore likely to be less
biased by attenuation by errors than those based on a single
measurement of BMI. In addition, FTO polymorphism was associ-
ated with parental BMI, as would be expected, given that offspring
share all genes with their parents (50% with each parent). The
slightly stronger association with maternal than paternal BMI may
reﬂect intrauterine inﬂuences of maternal obesity programming
increased life-long obesity risk in the offspring, non-paternity gen-
erating attenuated paternal associations, or random variation in
associations.
36–38
Secondly, FTO polymorphism was not associated with factors
such as sex, age, early or adult socioeconomic circumstances, edu-
cational attainment, smoking, or alcohol consumption. Thus, these
common confounding factors are unlikely to distort the instrumen-
tal variables analysis of the effect of BMI on atherosclerosis risk
(path b in Figure 1), as has been demonstrated previously.
39
Thirdly, as the FTO genotype determines the increased risk of
higher BMI levels from early life onwards, reverse causality
where subclinical atheroma affects risk factor levels was largely
eliminated.
A full understanding of the function of the FTO gene is under-
going further exploration. However, both high BMI and type 2 dia-
betes contribute to atherosclerotic vascular changes,
40–43 and an
additive effect of the FTO variant rs9939609 on BMI has been repli-
cated in at least 13 unselected independent population studies with
38 759 participants.
8 In the Avon Longitudinal Study of Parents and
Children (ALSPAC) offspring, the variant was shown to have a
speciﬁc association with fat mass.
8 In genome wide studies, the
FTO gene has been identiﬁed to predispose to type 2 diabetes
via an effect on BMI.
8 Furthermore, it has been shown that the
FTO gene is associated with insulin resistance, hyperglycaemia,
dyslipidaemia, and hypertension, as one would predict based on
observational evidence of the association of BMI with these out-
comes,
44 and of randomized trials of the effect of weight change
interventions on these outcomes.
44 These ﬁndings suggest that
greater adiposity is indeed causally related to these outcomes
and that the observational studies for these associations provide
............................................................................
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Table 4 Comparison of the association of lifetime BMI with carotid intima-media thickness (CIMT), blood pressure,
glucose, and insulin resistance obtained from ordinary least squares linear regression to that obtained from the
instrumental variables regression analysis
a
Outcome n Beta (95% CI) for outcome per 1 SD
increase in sex- and age-standardized lifetime BMI
z-score
P for difference in effect
size between the two
analytical approaches
Ordinary least squares
linear regression
Instrumental
variables analysis
a
Study population
Adult CIMT, mm 2211 0.011 (0.007 to 0.015) 0.048 (20.016 to 0.112) 0.23
P , 0.0001 P ¼ 0.15
Lifetime systolic BP, z-score 2204 0.36 (0.32 to 0.40) 0.95 (0.15 to 1.74) 0.09
P , 0.0001 P ¼ 0.02
Adult glucose, mmol/dL 2230 0.08 (0.05 to 0.12) 0.67 (20.02 to 1.35) 0.04
P , 0.0001 P ¼ 0.06
Adult HOMA index 2229 0.47 (0.40 to 0.55) 0.94 (20.34 to 2.22) 0.46
P , 0.0001 P ¼ 0.15
Simulated data
b
Adult CIMT, mm 7192 0.013 (0.011 to 0.016) 0.061 (0.020 to 0.101) 0.01
P , 0.0001 P ¼ 0.003
Lifetime systolic BP, z-score 7192 0.31 (0.29 to 0.33) 0.60 (0.30 to 0.89) 0.04
P , 0.0001 P , 0.0001
Adult glucose, mmol/dL 7192 0.09 (0.07 to 0.11) 0.72 (0.32 to 1.12) 0.0002
P , 0.0001 P , 0.0001
Adult HOMA index 7192 0.55 (0.51 to 0.60) 0.89 (0.14 to 1.64) 0.37
P , 0.0001 P ¼ 0.02
aIn instrumental variables regression analysis FTO polymorphism rs9939609 acts as an instrument for the unconfounded lifetime effect of BMI on CIMT and risk factors.
bPost hoc analysis with artiﬁcially generated larger sample (sample size equals two times baseline cohort).
M. Kivima ¨ki et al. 2558valid estimates of effect. Furthermore, these ﬁndings provide some
support that FTO polymorphism is a valid instrument for
adiposity. If it were not a valid instrument of adiposity, then one
would not expect such accurate prediction of the causal effect
of adiposity on outcomes that are generally widely accepted as
being causally related to greater adiposity,
45 and that alter in
relation to changes in BMI in randomized controlled trials of
drug and surgery treatments that reduce BMI.
46–48
Study limitations
Limitations of Mendelian randomization testing have been dis-
cussed in detail previously.
5 It is possible that FTO has other
direct phenotypic effects in addition to those on BMI, and it is
these that inﬂuence the outcomes. Furthermore, the expression
of FTO during early-life development could trigger a canalizing
response that would mitigate the effects of increased adiposity.
Studies utilizing additional independent genetic variants related to
BMI, and investigations of when, during development, the variants
begin to inﬂuence adiposity, could help resolve these issues. It
could be argued that, as adjustment for BMI did not abolish the
FTO-outcome associations, this suggests that there are indeed
alternative pathways linking FTO to the outcomes. However, it
must be remembered that even the repeat measures of BMI uti-
lized in our lifetime BMI score will not be an accurate indicator
of true lifetime adiposity, and a residual effect of FTO after adjust-
ment for our lifetime BMI measure would be expected even if the
entire effect of FTO was mediated through adiposity.
In this study, the wider conﬁdence intervals for effect estimates
from instrumental variables analysis compared with those obtained
from the standard regression models demonstrate a drawback.
Body mass index is a complex trait, and the small proportion of
variation in BMI explained by the genetic instrument based on a
single gene leads to the much lower precision of the instrumental
variables analysis estimates compared with the estimates from
standard regression models. Thus, the instrumental variable esti-
mates are typically less efﬁcient than the standard regression
estimates if there is no confounding, reverse causality, or measure-
ment error, but unlike the standard regression estimators the
instrumental variables estimates should remain consistent when
these are present. Besides supporting the role of BMI as a contri-
buting factor to CIMT and various atherosclerotic risk factors, our
ﬁndings suggest that the true inﬂuence of BMI on these factors
might be underestimated in cohort studies. However, larger
samples and/or stronger genetic instruments are needed before
this conclusion can be convincingly supported by statistically
robust results after correction for multiple testing. Furthermore,
as the function of FTO is not fully known, we cannot be certain
that the FTO polymorphism conferred effect on atherosclerosis
risk factors only through adiposity.
Conclusion
Mendelian randomization approach has different strengths and
limitations than conventional analysis. We found evidence that
genetic variants in the FTO gene were not related to potential con-
founding factors; that they were strongly associated with lifetime
BMI levels; and that the ﬁndings on the effects of lifetime BMI on
CIMT and atherosclerosis risk factors as obtained from Mendelian
randomization and standard regression models were converging.
These results suggest that Mendelian randomization approach
with FTO genotype data indeed have the potential of complement-
ing existing evidence on the effects of lifetime BMI on athero-
sclerosis risk in large cohorts of young adults.
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